Navigating intellectual property disputes requires strategic decisions on the most effective resolution paths. This session explores the full range of options available to tech companies—from mediation and arbitration to licensing, opposition, and litigation. Gain insight into when each tool is best suited, how to manage IP portfolios proactively, support innovation teams, and balance the operational and financial impact of disputes on your business.

• Explore the expanding role of mediation and arbitration as faster, cost-effective alternatives to traditional litigation in various IP disputes.

• Understand the potential impact of the new UPC Mediation and Arbitration Centre in Ljubljana, and how it may change dispute resolution for European patent holders and implementers.

• Understand how strategic licensing and portfolio management can help avoid costly conflicts and support innovation.

• Discuss when to escalate matters through opposition proceedings or litigation and how to prepare for large-scale enforcement campaigns globally.

With injunctions becoming a decisive battleground in global SEP and FRAND disputes before the German courts and UPC, this session explores how courts across key jurisdictions are shaping access to—and constraints on—injunctive relief. From the Vodafone/HMD matter in Germany to expanding dockets in Brazil, India, and China, this session unpacks strategic use of injunctions by both SEP holders and implementers, while spotlighting where legal frameworks may shift next. Explore how national courts and the UPC are interpreting proportionality, the influence of the European Commission, and the contrasting positions across global IP enforcement venues.

• Compare how courts in Germany, the UK, the UPC, and the US weigh proportionality, public interest, and enforcement policy when determining injunction relief in SEP cases
• Explore how jurisdictions like Brazil and Colombia are shaping global negotiations through low-cost, fast-granting preliminary injunctions and limited review of FRAND defences
• Discuss the possibilities of injunctive relief in the USA and a change from the eBay standard

Supplementary Protection Certificates remain a critical and complex aspect of pharmaceutical patent strategy. This session offers a comprehensive review of recent landmark rulings and evolving practices across Europe, providing life sciences patent holders with key insights to refine their SPC approaches in 2025.

• Explore pivotal cases such as Teva/MSD and Halozyme, and their impact on Articles 3(a), 3(c), and 1(b) concerning combination products and active ingredient interpretation.
• Understand how recent UK decisions, including Merck v Comptroller (2025), reflect divergence from broader European SPC practice, and examine emerging trends in antibody SPCs and unitary SPC legal status.
• Examine the expanded SPC Manufacturing Waiver regime since 2022, including conflicting rulings from Belgium, Germany, and the Netherlands on storage, export, and notification requirements.
• Gain practical guidance on managing waiver-related risks, protecting exclusivity, and navigating cross-jurisdictional challenges in SPC enforcement and litigation.